NeoGenomics, Inc.
neogenomics.com ↗In their words
“Our net promoter score of 79 reflects strong physician satisfaction among our current customer base with our NPS score continuing to improve in 2025, even with record test volumes. Two, we enjoy a leadership position in the hematology testing market, with greater than 25% share across diagnostics and therapy selection.”
“Combined, our broad portfolio of testing, leading market share in heme and ability to remove friction from our customers are helping deliver the strong results I've just mentioned. They also lead to an industry-leading customer experience as evidenced by our Net Promoter Score in the high 70s across both pathology and oncology.”
“NeoGenomics reported Net Promoter Scores in the high 70s across both segments as it expands its commercial representative force.”
Disclosed NPS over time
Every Net Promoter Score NeoGenomics, Inc. has published, by date.
NPS disclosures (5)
NeoGenomics reported Net Promoter Scores in the high 70s across both segments as it expands its commercial representative force.
NeoGenomics achieved a Net Promoter Score of 78 in a June 2026 study.
Combined, our broad portfolio of testing, leading market share in heme and ability to remove friction from our customers are helping deliver the strong results I've just mentioned. They also lead to an industry-leading customer experience as evidenced by our Net Promoter Score in the high 70s across both pathology and oncology.
Improved our Net Promoter Score to 79, up from 74 in 2024, reflecting strong physician satisfaction among our current customer base 2025 Annual Report — 3 $ in Thousands … Revenue … $727,332 % Growth … Net Loss … % Growth/(Decline) … Adjusted
Our net promoter score of 79 reflects strong physician satisfaction among our current customer base with our NPS score continuing to improve in 2025, even with record test volumes. Two, we enjoy a leadership position in the hematology testing market, with greater than 25% share across diagnostics and therapy selection.
Retention disclosures (0)
No retention figures yet.
28 earlier entries are in the full version. Get full access →
Lighthouse companies in Pharma, medtech & health distribution
About these figures
Every figure here was publicly disclosed by the named company: press releases, annual reports, SEC filings, earnings calls and news coverage. Companies tend to publish their NPS when it is good, so these numbers run higher than a true industry average: read them as what leading companies in this vertical say publicly, not as an industry benchmark.
NPS runs from −100 to +100. Retention figures are reported as the company defines them (net revenue retention, gross revenue retention, customer retention rate, churn). Every entry links to its source in the full database.